Artwork

Sisällön tarjoaa Going Anti-Viral. Going Anti-Viral tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

Episode 14 - HIV Treatment with Long-Acting Injectables with Dr Aadia Rana Recorded Live at CROI 2024 on March 4, 2024

26:39
 
Jaa
 

Manage episode 411549099 series 3516544
Sisällön tarjoaa Going Anti-Viral. Going Anti-Viral tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Episode 14 - HIV Treatment with Long-Acting Injectables with Dr Aadia Rana Recorded Live at CROI 2024 on March 4, 2024
In this episode, Dr Michael Saag and Dr Adia Rana discuss a breakthrough study on using a long-acting injectable HIV treatment with conditional economic incentives for individuals who were unable to take oral therapy. Presented at CROI 2024, the study's positive outcomes offer an effective option for certain individuals with no other options for continuing oral antiretroviral therapy.
For further reading, please visit the link below.

Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel

00:00 Introduction to the Podcast and Guest

00:50 Exploring Adherence Challenges and Study Insights

03:27 The Evolution of HIV Treatment: From Oral to Injectable Therapies

10:59 Study Results: A New Alternative for Select Individuals with Limited Treatment Options

16:05 Navigating Real-World Applications and Ethical Considerations

21:08 Reflecting on the Journey and Looking Ahead

25:21 Closing Thoughts and Future Directions

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

  continue reading

17 jaksoa

Artwork
iconJaa
 
Manage episode 411549099 series 3516544
Sisällön tarjoaa Going Anti-Viral. Going Anti-Viral tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Episode 14 - HIV Treatment with Long-Acting Injectables with Dr Aadia Rana Recorded Live at CROI 2024 on March 4, 2024
In this episode, Dr Michael Saag and Dr Adia Rana discuss a breakthrough study on using a long-acting injectable HIV treatment with conditional economic incentives for individuals who were unable to take oral therapy. Presented at CROI 2024, the study's positive outcomes offer an effective option for certain individuals with no other options for continuing oral antiretroviral therapy.
For further reading, please visit the link below.

Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel

00:00 Introduction to the Podcast and Guest

00:50 Exploring Adherence Challenges and Study Insights

03:27 The Evolution of HIV Treatment: From Oral to Injectable Therapies

10:59 Study Results: A New Alternative for Select Individuals with Limited Treatment Options

16:05 Navigating Real-World Applications and Ethical Considerations

21:08 Reflecting on the Journey and Looking Ahead

25:21 Closing Thoughts and Future Directions

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

  continue reading

17 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas